ArriVent BioPharma, Inc. Common Stock Income Statement
Concept
Total Revenue
YoY
Cost of Goods Sold (COGS)
Gross Profit
Operating expenses
Selling, General & Administrative
Research & Development
Operating Income
Interest Expense
Income Before Tax
Tax Provision
Net Income
YoY
Total Expenses
Net Interest Income
EBITDA
Reconciled Depreciation
EBIT
2022
0M
-
0M
0M
37M
6M
30M
-37M
0M
-37M
0M
-37M
0M
0M
0M
0M
0M
Concept
Total Revenue
YoY
Cost of Goods Sold (COGS)
Gross Profit
Operating expenses
Selling, General & Administrative
Research & Development
Operating Income
Interest Expense
Income Before Tax
Tax Provision
Net Income
YoY
Total Expenses
Net Interest Income
EBITDA
Reconciled Depreciation
EBIT
3Q2023
4Q2022
0M
-
0M
0M
17M
2M
14M
-17M
0M
-14M
0M
-14M
0M
2M
0M
0M
0M
0M
-
0M
0M
10M
2M
9M
-10M
0M
-10M
0M
-10M
0M
0M
0M
0M
0M